Literature DB >> 20163073

LASIK for myopia and astigmatism using the SCHWIND AMARIS excimer laser: an international multicenter trial.

Maria Clara Arbelaez1, Ioannis M Aslanides, Carmen Barraquer, Francesco Carones, Alena Feuermannova, Tobias Neuhann, Pavel Rozsival.   

Abstract

PURPOSE: To assess the efficacy, predictability, and safety of LASIK for the surgical correction of low to moderate myopia with astigmatism using the SCHWIND AMARIS excimer laser.
METHODS: Six international study sites enrolled 358 eyes with a manifest refraction spherical equivalent (MRSE) from -0.50 to -7.38 diopters (D) (mean sphere: -3.13+/-1.58 D) with up to -5.00 D of astigmatism (mean: -0.69+/-0.67 D). All eyes underwent treatment with the nonwavefront-guided aspheric algorithm of the SCHWIND AMARIS excimer laser. All eyes were targeted for emmetropia. Refractive outcomes and corneal higher order aberrations were analyzed pre- and postoperatively. Visual quality was assessed using photopic and mesopic contrast sensitivity. Six-month postoperative outcomes are reported.
RESULTS: At 6 months postoperative, the MRSE for all eyes was -0.21+/-0.20 D, and 96% (343/358) of eyes had MRSE within +/-0.50 D. Uncorrected visual acuity was 20/20 or better in 98% (351/358) of eyes, and no eyes lost 2 or more lines of best spectacle-corrected visual acuity. The total corneal higher order aberrations root-mean-square increased by 0.09 microm, spherical aberration increased by 0.08 microm, and coma increased by 0.04 microm postoperatively. Photopic and mesopic contrast sensitivity did not change 6 months postoperatively.
CONCLUSIONS: Treatment of myopia with astigmatism using the SCHWIND AMARIS excimer laser is safe, efficacious, predictable, and maintains visual quality.

Entities:  

Mesh:

Year:  2010        PMID: 20163073     DOI: 10.3928/1081597X-20100121-04

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

1.  Visual performance after conventional LASIK and wavefront-guided LASIK with iris-registration: results at 1 year.

Authors:  Jing Zhang; Yue-Hua Zhou; Rui Li; Lei Tian
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

2.  One-year refractive results, contrast sensitivity, high-order aberrations and complications after myopic small-incision lenticule extraction (ReLEx SMILE).

Authors:  Walter Sekundo; Jana Gertnere; Thomas Bertelmann; Igor Solomatin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-20       Impact factor: 3.117

3.  Comparison of Wavelight Allegretto Eye-Q and Schwind Amaris 750S excimer laser in treatment of high astigmatism.

Authors:  Maja Bohac; Alma Biscevic; Mateja Koncarevic; Marija Anticic; Nikica Gabric; Sudi Patel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-23       Impact factor: 3.117

Review 4.  Excimer Lasers in Refractive Surgery.

Authors:  Ajla Pidro; Alma Biscevic; Melisa Ahmedbegovic Pjano; Ivana Mravicic; Nita Bejdic; Maja Bohac
Journal:  Acta Inform Med       Date:  2019-12

Review 5.  Excimer laser 6(th) generation: state of the art and refractive surgical outcomes.

Authors:  Mohamed El Bahrawy; Jorge L Alió
Journal:  Eye Vis (Lond)       Date:  2015-03-01

6.  Long-term results of excimer laser procedure to correct astigmatic refractive errors.

Authors:  Anna M Roszkowska; Letteria De Grazia; Alessandro Meduri; Edward Wylegala; Pasquale Aragona
Journal:  Med Sci Monit       Date:  2013-11-04

7.  Refractive outcomes of an advanced aspherically optimized profile for myopia corrections by LASIK: a retrospective comparison with the standard aspherically optimized profile.

Authors:  Bertram Meyer; Georg Sluyterman van Langeweyde; Matthias Wottke
Journal:  Clin Ophthalmol       Date:  2015-02-23

8.  Outcomes of Wavefront-Optimized Laser-Assisted In-Situ Keratomileusis and Photorefractive Keratectomy for correction of Myopia and Myopic Astigmatism over One Year Follow-Up.

Authors:  Mohammad M Shehadeh; Mohammad T Akkawi; Ammar A Aghbar; Muna T Musmar; Malak N Khabbas; Marah F Kharouf; Liana Al-Labadi
Journal:  Open Ophthalmol J       Date:  2018-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.